| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 453.4 | 400.2 | 347.8 |
| Other income | 3.8 | 2.9 | 2.6 |
| Total income | 457.2 | 403.1 | 350.4 |
| Profit before exceptional items & tax | 31.3 | 27.9 | 25.4 |
| Profit before tax | 31.3 | 27.9 | 25.4 |
| Net profit | 24.6 | 21.6 | 20.6 |
| Operating margin | 6.8% | 6.9% | 7.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +19.40% |
|---|---|
| Net profit, quarter on quarter | +13.90% |
| Revenue, year on year | +30.40% |
NSE results filing, NSE: REMUS. Figures extracted from the filing.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹946.00
- Market cap
- ₹1,115 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 30.1×Sector 50.4×
- Promoter holding
- 70.95%
- FII holding
- 5.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Dividend
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the migration of its equity shares from the NSE Emerge platform to Main Board.
Remus Pharmaceuticals Merger & Restructuring
Remus Pharmaceuticals will incorporate a new subsidiary in the Dominican Republic for pharmaceutical distribution. The company will hold at least 51% of its share capital.
Remus Pharmaceuticals Management Change
Remus Pharmaceuticals Limited has appointed Mr. Ashutosh Naginbhai Valani as a Non-Executive Independent Director, effective September 2, 2026.
Remus Pharmaceuticals SME to Main Board Migration
Remus Pharmaceuticals' board approved the company's migration from the NSE SME Emerge platform to the Main Board. It also announced a new subsidiary in the Dominican Republic.
Remus Pharmaceuticals Earnings Call: Key Takeaways
Remus Pharmaceuticals delivered 38% YoY consolidated revenue growth for FY26. Management is shifting focus toward higher-margin B2C segments and niche formulations in Latin America and Southeast Asia.